The publication of a landmark Phase III trial in The Lancet in December 2025 has provided compelling evidence that proton therapy offers a significant survival advantage over traditional radiation for certain cancers, beginning to influence how cancer treatment infrastructure is planned across the United States. The study, led by The University of Texas MD Anderson Cancer Center, demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation.
This nearly 10-percentage-point survival gap represents some of the clearest evidence yet addressing a long-standing question in oncology: how much does the collateral radiation exposure from photon beams matter over a patient's lifetime? Unlike traditional radiation, where photon beams pass through the body and deposit an exit dose in tissue beyond the tumor, proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue. This clinical advantage is now driving new facility investments, including a proton center scheduled to open this summer in Boca Raton, Florida.
The trial, which enrolled 440 patients across 21 proton centers in the U.S., tracked outcomes over several years and represents the largest randomized Phase III comparison to date. The findings validate strategic moves by companies that anticipated this shift in radiation oncology. LIXTE Biotechnology Holdings Inc. implemented strategic expansion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform.
For decades, radiation oncology advanced incrementally through improved software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The recent data suggests the field may be entering a more transformative period. The study's implications extend beyond oropharyngeal cancer, potentially affecting treatment protocols for other cancers where minimizing radiation to adjacent critical structures is paramount. As evidence accumulates, the conversation among oncologists is shifting from whether collateral exposure matters to how treatment modalities should be selected to optimize long-term outcomes.
Investors and industry observers should note that certain statements in related communications are forward-looking and involve risks, uncertainties, and other factors that may cause actual results to differ materially from expectations. These statements are subject to numerous risks detailed in company filings with the SEC, including those discussed under the heading "Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K available through the SEC's EDGAR system at https://www.sec.gov/edgar.shtml. Parties undertake no duty to update this information unless required by law.
